TRIM37 Inhibitors

Chemical inhibitors of TRIM37 can impede the protein's function through various mechanisms by mainly targeting the ubiquitin-proteasome system, which is integral to its role in protein turnover and degradation. MG132, Bortezomib, Lactacystin, Epoxomicin, PI-1840, Withaferin A, Carfilzomib, Oprozomib, and Nelfinavir are proteasome inhibitors that lead to the accumulation of ubiquitinated proteins in the cell. By preventing the proteasome from degrading proteins tagged by TRIM37, these inhibitors can result in the disfunction of TRIM37 and an aberrant buildup of its substrates, which may interfere with cellular homeostasis. This accumulation can hinder TRIM37's ability to regulate protein quality control, as it relies on the proteasome to degrade proteins it has marked for destruction.

Additionally, Chloroquine and Concanamycin A disrupt the lysosomal degradation pathway. Chloroquine raises the pH in lysosomes, which may impair the degradation of proteins that TRIM37 has targeted for lysosomal degradation. Similarly, Concanamycin A, as a V-ATPase inhibitor, can disturb lysosomal acidification, potentially impeding the breakdown of TRIM37's substrates within the lysosome. By interfering with the degradation process in lysosomes, these inhibitors can indirectly inhibit the functionality of TRIM37 regarding proteins destined for this degradation pathway. Meanwhile, MLN4924 inhibits the NEDD8-activating enzyme, which is crucial for the neddylation process that modifies cullin-RING ubiquitin ligases, a class of enzymes that TRIM37 could be functionally associated with. Inhibition of this upstream process can have downstream effects on TRIM37's activity, as it may rely on the proper functioning of the neddylation pathway to exert its effects on protein ubiquitination and subsequent degradation.